The role of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in chemotherapy for lung cancer.
Saijo
N
N
Kanto Lung Cancer Chemotherapy Group (KLLCG), National Cancer Center Hospital (NCCH), Tokyo, Japan.
Eguchi
K
K
Etou
H
H
Miyachi
S
S
Morinari
H
H
Nakada
K
K
Noda
K
K
Ohkuni
Y
Y
Watanabe
K
K
Yamada
Y
Y
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D013713:Teniposide / Q000008:administration & dosage
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D013713:Teniposide; D002945:Cisplatin